Sai Life Sciences Limited IPO Review
Neutral549-549 · Mainboard
✦
Analyst Verdict
Sai Life Sciences Limited IPO
Neutral
IPO at a Glance
Price Band
549-549
Issue Size
3043cr
Min. Investment
₹14,823
Opens
2024-12-09
Closes
2024-12-11
Listing
2024-12-16
Category
Mainboard
Key Strengths
✓Integrated Indian CRDMO offering discovery, development, and manufacturing services.
✓Portfolio includes 50 late-phase and commercial products as of September 30, 2024.
✓Diverse mix of commercial drugs and under-development molecules with blockbuster potential.
✓CRDMO model enables proximity-based development and manufacturing in India.
✓Broad customer base, including top global pharmaceutical companies.
Key Risks
⚠Dependence on biotechnology and pharmaceutical customers subject to market and funding risks.
⚠R&D outcomes may fail to meet customer expectations, leading to project discontinuation.
⚠Low success rate in drug development impacts overall financial performance.
⚠Risks from international operations, including delays and regulatory challenges.
⚠Loss-making subsidiaries may adversely impact overall financials.
⚠Pricing pressure from customers may affect margins and profitability.
⚠High working capital requirements could strain financial resources.
⚠No proceeds from the Offer for Sale portion will benefit the company.
Frequently Asked Questions
Should I apply for Sai Life Sciences Limited IPO?
Based on our analysis, our rating for Sai Life Sciences Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Sai Life Sciences Limited IPO?
Dependence on biotechnology and pharmaceutical customers subject to market and funding risks. R&D outcomes may fail to meet customer expectations, leading to project discontinuation. Low success rate in drug development impacts overall financial performance.
What are the strengths of Sai Life Sciences Limited IPO?
Integrated Indian CRDMO offering discovery, development, and manufacturing services. Portfolio includes 50 late-phase and commercial products as of September 30, 2024. Diverse mix of commercial drugs and under-development molecules with blockbuster potential.
What is the price band of Sai Life Sciences Limited IPO?
The price band for Sai Life Sciences Limited IPO is 549-549. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more